virology

Poster Session Showcases IRP Graduate Students

Event Includes In-Person Presentations for First Time Since 2020

people looking at posters at the 2023 NIH Graduate Student Research Symposium poster session

Three years after COVID-19 dramatically changed the way scientists and many others work, much of life in the NIH IRP has begun to resemble the way things were in February of 2020. This includes the return of in-person scientific poster sessions like the one that took place on February 16 as part of the 19th annual NIH Graduate Student Research Symposium. Nearly 130 graduate students conducting their Ph.D. research in IRP labs as part of NIH’s Graduate Partnership Program presented their progress at that poster session and its virtual counterpart held February 15.

The two poster sessions made it clear that IRP graduate students are essential contributors to the life-changing discoveries made at NIH, from using geckos to learn about human eye diseases to investigating how the immune system combats infectious invaders to exploring ways to improve cancer treatment. Keep reading to learn about some of the bright scientists-in-training who showed off their work during the two-day event.

Leading the Charge Against Infectious Disease

Government Awards Recognize H. Clifford Lane’s Four Decades of Research Achievements

Dr. H. Clifford Lane

The remarkable career of H. Clifford Lane, M.D., might have gone very differently if a NIH scientist hadn’t accidentally eavesdropped on Dr. Lane’s conversation with a colleague in 1979. After hearing Dr. Lane mention that he had missed the deadline to apply for a position at NIH, the NIH researcher made some calls and discovered a spot there had just opened up — one that was perfect for Dr. Lane, who would spend the ensuing decades conducting life-saving research to understand and combat some of the world’s most dangerous infectious diseases.

Now the Clinical Director at the National Institute for Allergy and Infectious Disease (NIAID), Dr. Lane has been named a finalist for the 2022 Samuel J. Heyman Service to America Medals’ Career Achievement Award in recognition of his crucial contributions to the fight against HIV/AIDS, Ebola, COVID-19, and other illnesses. Also known as the “Sammies,” the awards recognize federal employees who are “breaking down barriers, overcoming huge challenges, and getting results.”

Three-Minute Talks Showcase Smooth-Talking Scientists

IRP Researchers Engage and Educate at Competition Finals

Three-Minute Talks poster

English is generally considered the ‘international language of science,’ since nearly all scientific papers are published in English. Yet, even to a native English speaker, scientists seem to be using another language entirely to talk about their research. Most Americans, after all, don’t know an ‘autophagosome’ from a ‘lysosome’ and would be hard-pressed to explain the difference between an ‘oocyst’ and a ’sporozoite.’

Fortunately, efforts like NIH’s annual Three-Minute Talks (TmT) competition are helping scientists learn how to communicate about their research in a manner that is much easier to understand. On June 30, after months spent whittling down dozens of competitors from across the IRP, 10 finalists raced against the clock to explain their work and its importance in a clear and compelling way.

IRP Scientists Continue Efforts to Quell Pandemic

COVID-19 Research at NIH Show No Signs of Slowing

SARS-CoV-2 virus particle

It’s been more than two years since the first outbreak of COVID-19 occurred in China. During that time, amazing scientific advances have dramatically altered prevention and treatment for the illness, including the development of remarkably safe and effective vaccines. However, even with widespread vaccination, scientists predict that the disease will continue to circulate in society indefinitely, with seasonal ebbs and flows like the flu.

As a result, even as COVID-19 vaccine shots rolled out by the hundreds of millions, numerous IRP researchers continued studying the disease and the virus responsible for it. Many of these projects have been funded by the NIH’s Intramural Targeted Anti-COVID-19 Program (ITAC), an initiative that provides IRP researchers with funding for research related to COVID-19. Over the past year and a half, ITAC has provided more than $12 million to support a wide variety of projects — more than can be covered in just one blog post. Read on to learn about just a handful of the many ways IRP researchers are contributing to the fight against COVID-19, and stay tuned next week for another blog describing even more ITAC-funded COVID research.

Study Explores Sex Differences in Flu

Differences in Flu-Fighting Antibodies Could Explain Women’s Greater Susceptibility

sick woman and man

It is well-known that COVID-19 infections are more often life-threatening in the elderly and individuals with chronic medical conditions like obesity, but the novel coronavirus isn’t the only infectious disease that more severely affects certain groups of people. A new IRP study explored a possible biological reason why women tend to experience worse flu infections and suggests a way to potentially improve the effectiveness of flu vaccines for everyone.

Postdoc Profile: COVID-19 Provides New Opportunities for Virus Science

Dr. Alberto D. López-Muñoz Pivots to New Research Focus Amidst Pandemic

Dr. Alberto D. López-Muñoz

Like all virologists, IRP postdoctoral fellow Alberto D. López-Muñoz, Ph.D., knew a global pandemic was sadly inevitable. No one could predict exactly when, but it was just a matter of time until a novel virus would make its way around the globe. Nevertheless, when the COVID-19 pandemic hit, caused by a virus called SARS-CoV-2, even Dr. López-Muñoz was surprised by how rapidly his career transformed as he switched gears study the novel contagion.

Global Scientists Come Together at the National Institutes of Health

Individuals From Around the World Drive IRP Breakthroughs

Dr. Flossie Wong-Staal

Come to NIH and you’ll hear many accents. Scientists from around the world have always contributed significantly to the NIH mission. The resulting diversity of backgrounds and perspectives makes the NIH Intramural Research Program an extremely stimulating and productive environment. Read on to learn about some of the many scientists of the past and present who brought their talents from abroad to one of the world’s leading institutions for biomedical research.

Old Drugs Find New Potential Against Hepatitis C

IRP Research Highlights a Novel Target to Stop Viral Infections

drug-screening robot

On July 28, health providers, researchers, patients, advocates, and governments across the globe observe World Hepatitis Day. Like this year’s theme, ‘Hepatitis Can’t Wait,’ IRP researchers are wasting no time utilizing the unique resources at the National Institutes of Health to identify innovative ways to combat the virus.

IRP Distinguished Investigator T. Jake Liang, M.D., for example, has focused his life’s work on understanding how hepatitis viruses infect, replicate, and persist in cells. The viruses he studies, hepatitis B and C, together affect more than 10 percent of the worlds’ population and are the most common causes of chronic liver disease and liver cancer. The two viruses were originally discovered in the 1980s by another IRP scientist, Harvey J. Alter, M.D., who shared the Nobel Prize in Medicine for that work in 2020. Nearly three decades later, Dr. Liang’s lab at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) worked with scientists at the National Center for Advancing Translational Sciences (NCATS) to develop a novel test to screen thousands of molecules using a technology called high-throughput screening, which led to the discovery of several compounds with the potential to block hepatitis C infection.

A Record-Breaking Sprint to Create a COVID-19 Vaccine

Kizzmekia Corbett and Barney Graham Recognized for Leading IRP Vaccine Research

Dr. Kizzmekia Corbett (left) and Dr. Barney Graham (right)

At the end of 2019, most people were planning for a typical busy year in 2020. The world was looking forward to the Summer Olympics in Japan, the U.S. was deep into election campaigns, and IRP scientists at NIH’s Vaccine Research Center (VRC) were designing vaccines for several coronaviruses in collaboration with a small biotech company called Moderna.

That all changed on a Saturday morning in early January. Chinese scientists had isolated a new coronavirus that was causing a serious epidemic in China’s Wuhan province and released its genetic sequence to the scientific community around the world. Barney Graham, M.D., Ph.D., director of the VRC’s Viral Pathogenesis Laboratory (VPL), and VRC research fellow Kizzmekia Corbett, Ph.D., dropped everything and immediately began working on a vaccine for the illness that would become known as COVID-19.

IRP’s Heinz Feldmann Elected to National Academy of Medicine

Vaccine Research Facilitated Rapid Response to Ebola Outbreak

Dr. Heinz Feldmann

IRP Senior Investigator Heinz Feldmann, M.D., was elected to the National Academy of Medicine (NAM) last year for leading the development of the technology that resulted in the first Ebola vaccine approved by the US Food and Drug Administration (FDA) and used by the World Health Organization (WHO) to combat the deadly disease. Election to the NAM is considered one of the highest honors in the fields of health and medicine.

As chief of the Laboratory of Virology at the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Feldmann’s work focuses on viruses like Ebola that cause hemorrhagic fever, a condition marked by fever, weakness, muscle pain, and sometimes bleeding. These highly contagious viruses require specialized laboratories and strict safety procedures to study.